
Aurobindo Pharma shares in focus after Unit 7 gets nine observations post US FDA inspection
Aurobindo Pharma’s Unit 7 is estimated to house over 150 cumulative ANDA filings (20% of the US portfolio).

Aurobindo Pharma’s Unit 7 is estimated to house over 150 cumulative ANDA filings (20% of the US portfolio).

Growth was led by the hospitals business, which posted a 15% on-year revenue increase, even as greenfield capacities were added.

The offer opens for non-retail investors on Wednesday, while retail investors can place their bids on Thursday.

As per Nuvama Alternative and Quantitative Research, AU Small Finance is estimated to see inflows of around $172 million, or 15.6 million shares, after the…

Management said that October was impacted by GST transition-related disruptions, but business momentum improved in November and December, with growth of around 12%.

Gold and silver prices rose as US yields fell. Indian investors moved to gold ETFs amid risks, with record AUM and steady SIPs, says Aditya…

Ford reported a $11.1 billion net loss in 2025, impacted by tariffs and Novelis Inc. factory fires, but revenue hit a record $187.3 billion and…

Alphabet Inc. raised nearly $32 billion in debt in 24 hours, including a rare 100-year sterling bond, to fund AI ambitions, with strong investor demand…

Q3 Results Live Updates: The December-quarter earnings season enters its final stretch on Wednesday, with a busy slate of results expected across sectors. Ashok Leyland,…

US markets closed mixed: S&P 500 and Nasdaq fell on weak retail sales and AI worries, while Dow hit a record high. Costco, Walmart, and…